Primary data analyses of MAESTRO-NAFLD-1 a 52 week double-blind placebo-controlled phase 3 clinical trial of resmetirom in patients with NAFLD
Publication
, Conference
Harrison, S; Taub, R; Neff, G; Moussa, S; Alkhouri, N; Bashir, M
Published in: JOURNAL OF HEPATOLOGY
July 2022
Duke Scholars
Published In
JOURNAL OF HEPATOLOGY
EISSN
1600-0641
ISSN
0168-8278
Publication Date
July 2022
Volume
77
Start / End Page
S14 / S14
Related Subject Headings
- Gastroenterology & Hepatology
- 3202 Clinical sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Harrison, S., Taub, R., Neff, G., Moussa, S., Alkhouri, N., & Bashir, M. (2022). Primary data analyses of MAESTRO-NAFLD-1 a 52 week double-blind placebo-controlled phase 3 clinical trial of resmetirom in patients with NAFLD. In JOURNAL OF HEPATOLOGY (Vol. 77, pp. S14–S14).
Harrison, Stephen, Rebecca Taub, Guy Neff, Sam Moussa, Naim Alkhouri, and Mustafa Bashir. “Primary data analyses of MAESTRO-NAFLD-1 a 52 week double-blind placebo-controlled phase 3 clinical trial of resmetirom in patients with NAFLD.” In JOURNAL OF HEPATOLOGY, 77:S14–S14, 2022.
Harrison S, Taub R, Neff G, Moussa S, Alkhouri N, Bashir M. Primary data analyses of MAESTRO-NAFLD-1 a 52 week double-blind placebo-controlled phase 3 clinical trial of resmetirom in patients with NAFLD. In: JOURNAL OF HEPATOLOGY. 2022. p. S14–S14.
Harrison, Stephen, et al. “Primary data analyses of MAESTRO-NAFLD-1 a 52 week double-blind placebo-controlled phase 3 clinical trial of resmetirom in patients with NAFLD.” JOURNAL OF HEPATOLOGY, vol. 77, 2022, pp. S14–S14.
Harrison S, Taub R, Neff G, Moussa S, Alkhouri N, Bashir M. Primary data analyses of MAESTRO-NAFLD-1 a 52 week double-blind placebo-controlled phase 3 clinical trial of resmetirom in patients with NAFLD. JOURNAL OF HEPATOLOGY. 2022. p. S14–S14.
Published In
JOURNAL OF HEPATOLOGY
EISSN
1600-0641
ISSN
0168-8278
Publication Date
July 2022
Volume
77
Start / End Page
S14 / S14
Related Subject Headings
- Gastroenterology & Hepatology
- 3202 Clinical sciences